Nasdaq grants MKDWELL Tech (MKDW) 180-day bid-price cure extension
Rhea-AI Filing Summary
MKDWELL Tech Inc. remains out of compliance with Nasdaq’s minimum bid price rule but has been granted more time to fix the issue. After failing to keep its ordinary share price at or above $1.00 for 30 consecutive business days during an initial 180‑day period that ended August 11, 2025, the company requested an extension. On August 13, 2025, Nasdaq granted an additional 180‑day grace period, until February 9, 2026, for MKDWELL to regain compliance.
Nasdaq’s decision reflects that MKDWELL meets all other continued listing requirements for the Nasdaq Capital Market apart from the bid price. The company has indicated it may use options such as a reverse stock split, if needed, to restore the price above $1.00 for at least 10 consecutive business days. If it cannot regain compliance within this extension, its shares could be subject to delisting, though the company would have the right to appeal.
Positive
- None.
Negative
- Ongoing Nasdaq bid‑price noncompliance and delisting risk: MKDWELL failed to regain the minimum $1.00 bid price in the first 180‑day period and now faces potential delisting if it cannot comply by February 9, 2026.
Insights
MKDWELL gets more time on Nasdaq but still faces delisting risk if its share price stays below $1.
Nasdaq has given MKDWELL Tech Inc. a second 180‑day window, until February 9, 2026, to cure its minimum bid price deficiency. The company already moved its listing to the Nasdaq Capital Market and currently meets all listing standards there except for the $1.00 bid requirement. This highlights that the core issue is the stock price level, not broader financial or governance criteria as presented.
To regain compliance, MKDWELL’s ordinary shares must close at or above $1.00 for at least 10 consecutive business days, and Nasdaq may require up to 20 days before confirming long‑term compliance. The company notes it may implement a reverse stock split of its outstanding common stock to help achieve this. If it fails to comply by February 9, 2026, its shares become subject to delisting, after which an appeal to a Nasdaq hearings panel would be possible but not assured of success.